fidaxomicin + metronidazole + vancomycin

This is a combination of three antibiotics—fidaxomicin, metronidazole, and vancomycin—used in the management of Clostridioides difficile infection (CDI). Each drug has a distinct mechanism of action targeting C. difficile bacteria: - **Fidaxomicin** is a macrocyclic antibiotic that inhibits the sigma-dependent transcription of bacterial RNA polymerases, leading to inhibition of protein synthesis and cell death. It is minimally absorbed from the gastrointestinal tract and acts locally in the gut. - **Metronidazole** is a nitroimidazole antibiotic that disrupts DNA synthesis by causing strand breakage after reduction within anaerobic organisms. - **Vancomycin** is a glycopeptide antibiotic that inhibits cell wall synthesis by binding to D-Ala-D-Ala termini in peptidoglycan precursors. This triple combination does not represent an established or standard regimen for CDI but may be considered in complex or fulminant cases where multiple agents are used sequentially or concurrently based on disease severity and patient factors. Typically, dual therapy with oral vancomycin plus intravenous metronidazole is recommended for fulminant CDI; fidaxomicin may be used as monotherapy or as part of sequential regimens[2][4][8]. There are limited data on simultaneous use of all three drugs together.